← Back to Clinical Trials
Recruiting NCT07027319

NCT07027319 The Effect of Triple P Training on Children's Repetitive Behaviors and Parents' Mood and Burnout Levels in Parents of Children With Autism

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07027319
Status Recruiting
Phase
Sponsor Özlem Teke
Condition Autism Spectrum Disorder
Study Type INTERVENTIONAL
Enrollment 70 participants
Start Date 2025-04-22
Primary Completion 2025-07-31

Eligibility & Interventions

Sex All sexes
Min Age 0 Years
Max Age 12 Years
Study Type INTERVENTIONAL
Interventions
Parenting Education

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 70 participants in total. It began in 2025-04-22 with a primary completion date of 2025-07-31.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

This project will be conducted in a private autism center in order to investigate the effects of Triple P training, which will be given to parents of children with Autism Spectrum Disorder, on the children's repetitive behaviors and the parents' burnout levels. The study is a randomized controlled trial and the study sample will consist of parents of children with Autism Spectrum Disorder. The children/parents included in the study sample will be numbered according to the order of arrival and 35 will be assigned to the intervention group and 35 will be assigned to the control group. During the randomization phase of the study, 70 children/parents with ASD will be randomly assigned to the intervention and control groups using Statistical Analysis Software. Data analysis will be performed using the Statistical Package for Social Sciences (SPSS v26.0, IBM Corp., Armonk, NY, USA). Descriptive data will be analyzed as mean, frequency and percentage. The conformity of quantitative data to normal distribution will be evaluated using the Kolmogorov-Smirnov test. Paired sample t-test will be used to compare dependent groups with normal distribution, independent sample t-test will be used to compare independent groups with normal distribution. P value will be considered significant if it is less than 0.05.

Eligibility Criteria

Inclusion Criteria: * Having a child diagnosed with Autism Spectrum Disorder between the ages of 0 and 12 * Being willing to participate in the study * Parents who speak Turkish Exclusion Criteria: * Parents of children with Autism Spectrum Disorder who are 13 years of age or older * Parents who do not speak Turkish

Contact & Investigator

Central Contact

Özlem Teke, MAS

✉ ozlem.teke@st.uskudar.edu.tr

📞 +905538035311

Principal Investigator

Elçin Babaoğlu, Asst. Prof. Dr.

STUDY DIRECTOR

Uskudar University

Frequently Asked Questions

Who can join the NCT07027319 clinical trial?

This trial is open to participants of all sexes, aged 0 Years or older, up to 12 Years, studying Autism Spectrum Disorder. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07027319 currently recruiting?

Yes, NCT07027319 is actively recruiting participants. Contact the research team at ozlem.teke@st.uskudar.edu.tr for enrollment information.

Where is the NCT07027319 trial being conducted?

This trial is being conducted at Istanbul, Turkey (Türkiye).

Who is sponsoring the NCT07027319 clinical trial?

NCT07027319 is sponsored by Özlem Teke. The principal investigator is Elçin Babaoğlu, Asst. Prof. Dr. at Uskudar University. The trial plans to enroll 70 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology